Combination therapy of infliximab and cyclosporin in the treatment of recalcitrant psoriasis. A case series

Abstract

In the systemic treatment of moderate-to-severe psoriasis, monotherapy is usually effective. However, some patients require combination therapy to adequately control their disease^1,2. In fact, data from recent european reports indicate that biological therapy is given concomitantly with traditional systemic drugs in up to 30% of psoriasis patients^1,3. Combination therapy of cyclosporin (CyA) with biologic drugs, particularly etanercept and adalimumab, has been rarely reported in the literature, including non-randomized trials and case reports^1,4-8.

This article is protected by copyright. All rights reserved.

http://ift.tt/2gyMN0B